# PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

> **NCT06409936** · PHASE2 · RECRUITING · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 160 (estimated)

## Conditions studied

- CML, Chronic Phase
- Chronic Myeloid Leukemia, Chronic Phase
- Chronic Myeloid Leukemia, BCR/ABL-Positive
- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Asciminib
- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT06409936
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-26
- **Primary completion:** 2029-06
- **Final completion:** 2032-06
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06409936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06409936, "PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06409936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*